Search

Objective: This study aims to analyze saliva composition in crack users using vibrational spectroscopy., Material and Methods: A total of 90 participants were meticulously selected and divided into three groups, each comprising 30 individuals. All participants met the criterion of having no observable clinical changes in the oral mucosa. The groups included active crack users with a minimum usage duration of 30 days, ex-crack users, and non-crack users. Rigorous inclusion and exclusion criteria were applied during participant selection to ensure the study's precision. Saliva analysis was performed using vibrational spectroscopy with FTIR (Fourier-transform Infrared spectroscopy)., Results: Pre-processed spectra enabled statistical comparability. Salivary biomarkers revealed clinical implications, including findings related to xerostomia, caries, and periodontal or systemic conditions such as lung cancer., Conclusion: The research uncovers significant compositional differences in the saliva of current users, former users, and non-users of crack. This nuanced understanding contributes to the discourse on substance abuse, highlighting the potential of saliva analysis for discerning different stages of crack use. The investigation suggests options for further exploration in clinical and forensic contexts, promising advancements in addiction research and diagnostics., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 Published by Elsevier Ltd.)

Ten male patients with peripheral vascular disease, Type 2 (LaFontaine), were randomly assigned in a double-blind study to receive either Na2 ethylene diamine tetra acetic acid (EDTA) plus MgSO4, B complex, and vitamin C, or a placebo of MgSO4, B complex, and vitamin C in Ringer's lactate solution. A total of 20 intravenous infusions were planned for administration to each patient. Clinical and laboratory (noninvasive) tests showed dramatic improvements after 10 infusions in some patients, and thus was broken the code indicating who was receiving EDTA and who was receiving placebo. The group that improved had been receiving EDTA; there was no change in the placebo group. The trial was then completed in a single-blind fashion. Patients originally assigned to receive placebo then received 10 EDTA infusions, while the group originally assigned to EDTA received 20 EDTA infusions. The group that had formerly received placebo showed improvements comparable to those seen in the first EDTA group after 10 treatments.